Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over one-fourth of the global adult population and is the leading cause of liver disease worldwide. To address this, the Asian Pacific Association for the Study of the Liver (APASL) has created clinical practice guidelines focused on MAFLD. The guidelines cover various aspects of the disease, such as its epidemiology, diagnosis, screening, assessment, and treatment. The guidelines aim to advance clinical practice, knowledge, and research on MAFLD, particularly in special groups. The guidelines are designed to advance clinical practice, to provide evidence-based recommendations to assist healthcare stakeholders in decision-making and to improve patient care and disease awareness. The guidelines take into account the burden of clinical management for the healthcare sector.

代谢功能障碍相关性脂肪肝（MAFLD）影响着全球四分之一以上的成年人，是全球肝病的主要病因。为此，亚太肝病研究协会（APASL）制定了以代谢功能障碍相关性脂肪肝为重点的临床实践指南。指南涵盖了该疾病的各个方面，如流行病学、诊断、筛查、评估和治疗。该指南旨在促进有关MAFLD的临床实践、知识和研究，尤其是在特殊群体中。该指南旨在推动临床实践，提供循证建议以协助医疗保健相关方做出决策，并改善患者护理和提高对疾病的认识。指南考虑到了临床管理给医疗保健部门带来的负担。